Novel Nucleoside L-BHDU for Treatment of Shingles and Chicken Pox
- Countries
- United States
- Application No.
- 8,492,362
- *Abstract
-
Application(Product)
· Therapeuticto treat Varicella Zoster Virus (chicken pox, shingles) infections
· Mayalso be used to treat Epstein Barr (mononucleosis) and HHV-8 (Kaposi’s sarcoma)virus infections
· Canbe used in conjunction with 5-fluorouracil to increase the cancer drug’smetabolic half-life in cancer patients
· Canbe used in combination with agents or other therapeutic treatments
ProblemsAddressed (benefits/advantages)
· Morepotent than current approved drugs, which also have issues with low oralbioavailability and drug resistance
· Easyto dose; ideal for elderly patients who may have difficulty with othertreatment options such as acyclovir, due to age-related changes in renalfunction
· Canbe used in immunodeficient and immunocompromised patients
· Canbe used in cancer patients as L-BHDU does not interfere with 5-fluorouracilcatabolism
TechnologySummary
Varicella zoster virus (VZV) is the causative agent ofchicken pox upon primary infection and shingles upon reactivation fromlatency. VZV disease is partiallypreventable by vaccination, but the incidence of shingles in older adultscontinues to rise as the vaccine efficacy is only approximately 50%. Therefore, there is a continued demand forantiviral drugs for VZV as current treatments are only moderately effective andrequire administration within 72 hours of rash onset for best results.
To address these concerns, UGA scientists have generated thenucleoside L-BHDU and related analogs. This compound has demonstrated high activity against VZV as well as EBV,and HV-8 viruses, in combination with low toxicity to the host cells. Becauseof its low toxicity, L-BHDU may be able to be administered to immunocompromisedand immunodeficient patients, such as patients with AIDS. Additionally, L-BHDUhas the unexpected property of increased the retention of the cancertherapeutic 5-fluorouracil, which is making this a good treatment option forindividuals with both viral infection and cancer.
Inventors
· DavidChu, Distinguished Research Professor Emeritus, Department of Pharmaceuticaland Biomedical Sciences
http://pbs.rx.uga.edu/people/faculty-members/david-chu/
Dr. Chu’s laboratory focuses on nucleoside and carbohydratechemistry, antiviral chemotherapy, cancer chemotherapy, structure-based drugdesign and molecular modeling and antiviral drug discovery for bioterrorism.Chu’s antiviral drug clevudine, marketed under the trade names Levovir andRevovir, is used in the treatment of chronic hepatitis B infections in SouthKorea and the Philippines. Chu holds 63 U.S. patents and more than130 international patents that have been licensed to 10 companies.
TechnologyDevelopment and IP Status
· Pre-clinicalstage
· USPatent No. 8,492,362
· Journalpublication: C. De et al. / AntiviralResearch 110 (2014) 10–19
- *IP Issue Date
- None
- *IP Type
- Utility
- Country/Region
- USA
